738 related articles for article (PubMed ID: 23523521)
21. Risk factors for and impact of carbapenem-resistant Acinetobacter baumannii colonization and infection: matched case-control study.
Henig O; Weber G; Hoshen MB; Paul M; German L; Neuberger A; Gluzman I; Berlin A; Shapira C; Balicer RD
Eur J Clin Microbiol Infect Dis; 2015 Oct; 34(10):2063-8. PubMed ID: 26205665
[TBL] [Abstract][Full Text] [Related]
22. Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
Liang CA; Lin YC; Lu PL; Chen HC; Chang HL; Sheu CC
Clin Microbiol Infect; 2018 Aug; 24(8):908.e1-908.e7. PubMed ID: 29108947
[TBL] [Abstract][Full Text] [Related]
23. Risk factors of mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia.
Liu CP; Shih SC; Wang NY; Wu AY; Sun FJ; Chow SF; Chen TL; Yan TR
J Microbiol Immunol Infect; 2016 Dec; 49(6):934-940. PubMed ID: 25553994
[TBL] [Abstract][Full Text] [Related]
24. Wide dissemination of OXA-23-producing carbapenem-resistant Acinetobacter baumannii clonal complex 22 in multiple cities of China.
Fu Y; Zhou J; Zhou H; Yang Q; Wei Z; Yu Y; Li L
J Antimicrob Chemother; 2010 Apr; 65(4):644-50. PubMed ID: 20154023
[TBL] [Abstract][Full Text] [Related]
25. Risk factors for 30-day mortality in patients with carbapenem-resistant Acinetobacter baumannii during an outbreak in an intensive care unit.
Prates CG; Martins AF; Superti SV; Lopes FS; Ramos F; Cantarelli VV; Zavascki AP
Epidemiol Infect; 2011 Mar; 139(3):411-8. PubMed ID: 20513254
[TBL] [Abstract][Full Text] [Related]
26. Risk factors for carbapenem-resistant Acinetobacter baumanii blood stream infections in a neonatal intensive care unit, Delhi, India.
Kumar A; Randhawa VS; Nirupam N; Rai Y; Saili A
J Infect Dev Ctries; 2014 Aug; 8(8):1049-54. PubMed ID: 25116673
[TBL] [Abstract][Full Text] [Related]
27. [Analysis of drug resistance of Acinetobacter baumannii and its related factors in ICU].
Ma MY; Xu J; Yu N; Huang GM
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2013 Nov; 25(11):686-9. PubMed ID: 24225215
[TBL] [Abstract][Full Text] [Related]
28. Bacteremic nosocomial pneumonia caused by Acinetobacter baumannii and Acinetobacter nosocomialis: a single or two distinct clinical entities?
Lee YT; Kuo SC; Yang SP; Lin YT; Chiang DH; Tseng FC; Chen TL; Fung CP
Clin Microbiol Infect; 2013 Jul; 19(7):640-5. PubMed ID: 22967204
[TBL] [Abstract][Full Text] [Related]
29. Predictors of mortality in patients infected with carbapenem-resistant Acinetobacter baumannii: A systematic review and meta-analysis.
Du X; Xu X; Yao J; Deng K; Chen S; Shen Z; Yang L; Feng G
Am J Infect Control; 2019 Sep; 47(9):1140-1145. PubMed ID: 31003750
[TBL] [Abstract][Full Text] [Related]
30. Emergence and spread of carbapenem-resistant strains of Acinetobacter baumannii in a tertiary-care hospital in Poland.
Wroblewska MM; Towner KJ; Marchel H; Luczak M
Clin Microbiol Infect; 2007 May; 13(5):490-6. PubMed ID: 17331123
[TBL] [Abstract][Full Text] [Related]
31. Clinical characteristics and outcomes of community and hospital-acquired Acinetobacter baumannii bacteremia.
Chusri S; Chongsuvivatwong V; Silpapojakul K; Singkhamanan K; Hortiwakul T; Charernmak B; Doi Y
J Microbiol Immunol Infect; 2019 Oct; 52(5):796-806. PubMed ID: 31031096
[TBL] [Abstract][Full Text] [Related]
32. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp.
Oliveira MS; Prado GV; Costa SF; Grinbaum RS; Levin AS
J Antimicrob Chemother; 2008 Jun; 61(6):1369-75. PubMed ID: 18367459
[TBL] [Abstract][Full Text] [Related]
33. Carbapenem-resistant Acinetobacter baumannii infections after organ transplantation.
Reddy P; Zembower TR; Ison MG; Baker TA; Stosor V
Transpl Infect Dis; 2010 Feb; 12(1):87-93. PubMed ID: 19735384
[TBL] [Abstract][Full Text] [Related]
34. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii.
Motaouakkil S; Charra B; Hachimi A; Nejmi H; Benslama A; Elmdaghri N; Belabbes H; Benbachir M
J Infect; 2006 Oct; 53(4):274-8. PubMed ID: 16442632
[TBL] [Abstract][Full Text] [Related]
35. Changes in the early mortality of adult patients with carbapenem-resistant Acinetobacter baumannii bacteremia during 11 years at an academic medical center.
Choi SH; Cho EB; Chung JW; Lee MK
J Infect Chemother; 2019 Jan; 25(1):6-11. PubMed ID: 30342838
[TBL] [Abstract][Full Text] [Related]
36. Exposure to quinolones is associated with carbapenem resistance among colistin-susceptible Acinetobacter baumannii blood isolates.
Kopterides P; Koletsi PK; Michalopoulos A; Falagas ME
Int J Antimicrob Agents; 2007 Nov; 30(5):409-14. PubMed ID: 17851052
[TBL] [Abstract][Full Text] [Related]
37. Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis.
Lemos EV; de la Hoz FP; Einarson TR; McGhan WF; Quevedo E; Castañeda C; Kawai K
Clin Microbiol Infect; 2014 May; 20(5):416-23. PubMed ID: 24131374
[TBL] [Abstract][Full Text] [Related]
38. Outbreak of resistant Acinetobacter baumannii- measures and proposal for prevention and control.
Romanelli RM; Jesus LA; Clemente WT; Lima SS; Rezende EM; Coutinho RL; Moreira RL; Neves FA; Brás Nde J
Braz J Infect Dis; 2009 Oct; 13(5):341-7. PubMed ID: 20428632
[TBL] [Abstract][Full Text] [Related]
39. The significance of Acinetobacter baumannii bacteraemia compared with Klebsiella pneumoniae bacteraemia: risk factors and outcomes.
Robenshtok E; Paul M; Leibovici L; Fraser A; Pitlik S; Ostfeld I; Samra Z; Perez S; Lev B; Weinberger M
J Hosp Infect; 2006 Nov; 64(3):282-7. PubMed ID: 16930770
[TBL] [Abstract][Full Text] [Related]
40. Treatment of Acinetobacter infections.
Michalopoulos A; Falagas ME
Expert Opin Pharmacother; 2010 Apr; 11(5):779-88. PubMed ID: 20210684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
